Month: July 2018

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (2nd line treatments)

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (2nd line treatments)

What Happen When First-Line Treatment Fails? In advanced or metastatic breast cancer, first-line treatment will fail after certain duration of time. This is because cancer cells developed resistance to the treatment and not because the treatment is ineffective. Life doesn't end when first-line treatment fails. We just continue fighting the cancer with other effective second-line … Continue reading Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (2nd line treatments)

News: Chemotherapy Kill Cancer Patients. Not Cancer?

News: Chemotherapy Kill Cancer Patients. Not Cancer?

Points Across The study published in reputable The Lancet Oncology journal emphasised on proper selection of cancer patients for chemotherapy treatment, especially patients who are old or have poor performance status. importance of mortality review in order to improve clinical decision making (identifying patients who does not benefit or not suitable for chemotherapy treatment, eg. … Continue reading News: Chemotherapy Kill Cancer Patients. Not Cancer?

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (1st line treatments)

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (1st line treatments)

Introduction HER2 over-expression constitutes around 20% of all breast cancer. Two different methods are being used to test for HER2 over-expression, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) Immunohistochemistry (IHC); identifies HER2 expression on the cell surface, with a grading system of 0 to 3+ positive. tumors are classed as HER2-positive if they have … Continue reading Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (1st line treatments)

Living Longer: Advanced Breast Cancer (ABC) – Triple Negatives; ER/PR/HER2 (-ve)

Living Longer: Advanced Breast Cancer (ABC) – Triple Negatives; ER/PR/HER2 (-ve)

Introduction Breast cancer is not a single disease but comprised of distinct biological subtypes with different prognosis and treatment options: Luminal A: ER/PR+ve, Her2-ve Luminal B: ER/PR+ve, Her2+ve HER2 over-expressed: Her2+ve Triple negatives/ basal-like: ER/PR-ve, Her2−ve Among the different subtypes above, triple negative breast cancer (TNBC) accounts for 10%-15% of breast cancer diagnosed. TNBC carries the worst prognosis and … Continue reading Living Longer: Advanced Breast Cancer (ABC) – Triple Negatives; ER/PR/HER2 (-ve)

Living Longer with Advanced/ Stage 4 Renal Cell Cancer ~ 1st Line Treatment (Treatment Naive/ No Previous Treatment)

Living Longer with Advanced/ Stage 4 Renal Cell Cancer ~ 1st Line Treatment (Treatment Naive/ No Previous Treatment)

Brief In Malaysia, renal cell cancer (RCC) or kidney cancer present at stage 4 in 50% of cases. More cases are detected incidentally during imaging (USG, CT scans) than those who present with the classical triad of flank pain, gross hematuria and palpable abdominal mass. Histologically, 80% are of clear cell type and almost all studies and … Continue reading Living Longer with Advanced/ Stage 4 Renal Cell Cancer ~ 1st Line Treatment (Treatment Naive/ No Previous Treatment)